128120-93-4Relevant academic research and scientific papers
NOVEL BENZIMIDAZOLE DERIVATIVES
-
Paragraph 0186, (2020/01/22)
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
DICARBAMATE INHIBITORS OF NS5A FOR TREATMENT OF HEPATITIS C VIRUS INFECTIONS AND RELATED DISEASES
-
Page/Page column 46; 47, (2020/11/03)
Dicarbamate compounds as inhibitors of NS5A, and therapeutic uses and methods of preparation thereof, are disclosed. These compounds, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodmgs, and pharmaceutical compositions t
Synthesis method of starting raw material for daclatasvir
-
Paragraph 0022; 0025, (2018/05/16)
The invention relates to a synthesis method of a starting raw material for daclatasvir. The synthesis method comprises the following steps of enabling 2,4'-dibromoacetophenone as shown in a formula I,L-BOC-proline as shown in a formula II, potassium carbo
PROCESS FOR THE PREPARATION OF CARBAMIC ACID, N,N'-[[1,1'-BIPHENYL] -4,4'-DIYLBIS]- 1 H-IMIDAZOLE-5,2 DIYI-(2S)-2,1-PYRROLIDINEDIYL[(1 S)-1-(1-METHYLETHYL)-2-OXO-2,1-ETHANEDIYL]]] BIS-,C,C'-DIMETHYL ESTER AND ITS SALTS AND POLYMORPHS
-
Page/Page column 31-32, (2018/08/20)
The present invention relates to the process for the preparation of carbamic acid, N,N'-[[1,1'biphenyl]- 4,4'-diylbis[ I H-imidazole-5,2-diyl-(2S)-2, 1-pyrrolidinediyl[ (1S)-1-( 1-methylethyl)-2- oxo-2,1-ethanediyl]]]bis-,C,C'-dimethyl ester of formula (I
HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS
-
Paragraph 0188; 0189, (2017/12/17)
A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.
Hepatitis C virus inhibitors
-
Page/Page column 179, (2017/07/06)
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: [in-line-formulae]Q-G-A-L-B—Z—W??(I),[/in-line-formulae] which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
As hepatitis c inhibitor spiro compound and its use in medicine
-
Paragraph 0849-0851, (2017/12/28)
The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.
Hepatitis c polymerase inhibitors
-
Paragraph 0046; 0062-0064, (2017/08/25)
The invention relates to a 4,4'-bis(2-((S)-pyrrolidine-2-yl)-1H-imidazole-4-yl)biphenyl type compound and a derivative therefore. The compound disclosed by the invention is a hepatitis c virus (HCV) polymerase inhibitor, has HCV resistant activity and can
9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF
-
Paragraph 0142-0143, (2016/10/31)
The present invention belongs to the field of chemical pharmaceuticals, and specifically relates to compounds represented by formula I having a 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene structure and being able to inhibit hepatitis C virus activity, or a pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug of said compounds, a pharmaceutical composition containing said compounds, and an application of said compounds or composition in the preparation of a drug. The compounds of the present invention have a good HCV inhibitory effect.
SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 0265-0268, (2015/11/09)
Disclosed are spiro compounds of formula (I), or stereomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof. The compounds can be used to treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore disclosed are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions in the treatment of HCV infection or hepatitis C disease.
